January 22, 2019 8:18am
The cold bucket of water is in the form of the upcoming splash of Q4 LPS (loss-per-share) earnings
… And cash positions re spending and “runways”
I’d start with enterprise value versus market cap disparities, return on equity, and short % of float, ATM utilizations and those companies that keep pushing payables and liabilities forward
Never forgetting regulatory status – the claim to a possible fame!
Pre-open indication: 1 BUY, 3 SELLs and 2 TRADEs
I answer one question, in which company should investors put, keep and commit their money!
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.
U.S. stock index futures pointing to a decline
Dow futures are DOWN -0.62% (-152 points) and NASDAQ futures are DOWN -0.78% (-53 points)
Futures are indicating that indexes are set for a rocky start on Tuesday;
European markets lower amid global growth concerns;
Asian equities declined as investor sentiment dipped on concerns about the global outlook, after the International Monetary Fund (IMF) slashed its world economic growth forecast on Monday.
The iShares Nasdaq Biotechnology (IBB) is NOT indicating in the pre-market
The SPDR S&P Biotech ETF (XBI) is indicating a NEGATIVE -0.49% DOWNSIDE
The Health Care Select Sector SPDR ETF (XLV) is indicating a NEGATIVE -0.29% in the pre-market
The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.52% DOWNSIDE
... U.S. stocks did not trade on Monday because of Martin Luther King Jr. Day.
The cause and effect issues, Asian stocks struggled for gains on Tuesday amid concerns about the global economic outlook after the International Monetary Fund (IMF) slashed its global growth forecast on Monday, warning that the economic momentum observed in recent years is decelerating.
Another ripple, the U.K. inches closer to its official departure date from the European Union of March 29 with no deal in sight, leaving the country with the possibility of crashing out of the EU without a formal agreement — something that business leaders and industry experts have been warning about since the negotiations began <CNBC>.
Friday’s losing post, “mutable values, the mother of the sector relies on the future in many companies, the upside share pricing history could be weakening!”
I also stated, “The question to be answered … this week will the oversold become the overbought?”
Friday’s night’s percentage (%) indicators: thin
- Review the range of the 30 upside from +0.06% (HSGX) to +9.97% (CUR +$0.037) while the 13 downside ranged from -0.18% (CLLS) to -8.04% (ONVO) with 2 flat closes (BLCM and PSTI).
Volume stat: low
- 10 out of the 30 upside had higher (than the 3 month average) volume
- 4 out of the 13 downside experienced greater volume (than the 3 month average) volume
In 14 sessions in January – there was 9 positive closes, 1 holiday and 4 negative closes – so far!
Companies in my headlights – It’s your decision; I provide an idea and context:
Two with news:
uniQure (QURE) closed up +$0.13 to $31.36. QURE starts a short week with the U.S. FDA has completed its review of an IND application for AMT-130, and the IND is now effective allowing uniQure to begin its planned P1/2 study. AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a micro-RNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients – BUY;
CRISPRS Therapeutics (CRSP) closed up +$1.25 to $37.13. CRSP and ProBioGen, a German service and technology provider, announced multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise. Technical and financial details of the collaboration were not disclosed. The collaboration includes a license option for CRISPR Therapeutics upon successful completion of the research goals. The pre-market indication is a negative -$2.53 or -6.81% – SELL;
Down markets and strength issues:
bluebird bio (BLUE) closed up +$3.46 to $129.96. BLUE seems to be a target for traders; in five (5) sessions, BLUE has a +12% or +$14.68 premium and a +16% or +$19.72 premium in eight (8) sessions – SELL into strength;
Sage Therapeutics (SAGE) closed up +$3.33 to $139.79. In eight (8) sessions, SAGE has an approximate $19.97 or +15% premium – SELL into strength;
Editas Medicine (EDIT) closed down again -$0.07 to $26.14 after Thursday’s -$0.13 to $26.21 after Wednesday’s -$0.14 to $26.26 after Tuesday’s up +$1.41 to $26.40 after Monday’s -$1.21 to $24.99. There is a negative -$0.04 or -0.15% pre-market indication – TRADE;
Intellia Therapeutics (NTLA) closed up +$0.28 to $15.20 after Thursday’s -$0.10 to $14.92 after Wednesday’s +$0.77 to $15.02 after Tuesday’s +$0.73 to $14.25 after Monday’s -$0.56 to $13.53. Frothy in this market says – TRADE;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.